POELLATH Advises SK Pharma on Sale to Arcus Infrastructure

London/Bielefeld — Arcus Infra­struc­ture Part­ners (“Arcus”), an invest­ment firm specia­li­zing in infra­struc­ture invest­ments, has acqui­red SK Pharma Logi­stics GmbH (“SK Pharma”), a provi­der of logi­stics solu­ti­ons for the health­care indus­try in Germany, through its Arcus Euro­pean Infra­struc­ture Fund 4. SK Pharma’s exis­ting manage­ment team will retain a stake in the company. The tran­sac­tion is still subject to the custo­mary regu­la­tory appr­ovals and is expec­ted to close in the fourth quar­ter of 2026. POELLATH provi­ded legal coun­sel to SK Pharma’s manage­ment regar­ding a manage­ment equity stake as part of the transaction. 

SK Pharma, based in Biele­feld, is one of the leading specia­li­zed logi­stics provi­ders for the health­care indus­try in Germany. With a network of eight warehouse loca­ti­ons in northwes­tern Germany, the company has appro­xi­m­ately 85,000 m² of tempe­ra­­ture-control­­led warehouse space and more than 100,000 pallet spaces. SK Pharma’s custo­mer base includes phar­maceu­ti­cal manu­fac­tu­r­ers, importers, whole­sa­lers, and other compa­nies in the health­care sector. In addi­tion to its GMP- and GDP-compli­­ant warehousing and distri­bu­tion infra­struc­ture, the company offers a wide range of comple­men­tary services and enables close opera­tio­nal, regu­la­tory, and digi­tal inte­gra­tion with its custo­mers’ proces­ses. The German market for outsour­ced phar­maceu­ti­cal logi­stics is expe­ri­en­cing struc­tu­ral growth, driven by demo­gra­phic trends, incre­asing outsour­cing, and rising regu­la­tory requi­re­ments. With its specia­li­zed infra­struc­ture and many years of indus­try exper­tise, SK Pharma is excep­tio­nally well-posi­­tio­­ned in this market. 

Arcus is an inde­pen­dent invest­ment firm focu­sed on mid-sized infra­struc­ture compa­nies with sustainable growth poten­tial, parti­cu­larly in the digi­tal, trans­por­ta­tion and logi­stics, indus­trial, and energy sectors.

Manage­ment Consul­tant for SK Pharma: POELLATH

Dr. Bene­dikt Hohaus (Part­ner, Manage­ment Buyouts, M&A/Private Equity)
Silke Simmer, LL.M. (Coun­sel, Manage­ment Buyouts, M&A/Private Equity)
Nata­lie Tafel­ski (Asso­ciate, Manage­ment Buyouts, M&A/Private Equity) 

www.pplaw.de